The median overall survival was 38.21 months with radium-223 plus enzalutamide and 32.62 months with enzalutamide alone. For patients with metastatic castration-resistant prostate cancer (mCRPC) with ...
The FEATURE study provides the first prospective validation of FDG-PET/CT and PERCIST response criteria in patients presenting with bone-only or bone-dominant metastatic breast cancer, opening the ...
Bone marrow metastasis (BMM) from non-hematolymphoid malignancies with resultant cytopenia (s) can mimic primary hematolymphoid disorders. This study aimed to investigate the clinical and pathological ...
In this phase 3 study, researchers aimed to determine whether adding radium-223 to enzalutamide improves survival outcomes in mCRPC with bone metastases. Renal and Urology News, a trusted source of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results